Home » New Role for NICE: Incremental Benefits Evaluation, Assessment
New Role for NICE: Incremental Benefits Evaluation, Assessment
November 17, 2010
The UK’s National Institute for Health and Clinical Excellence (NICE) will continue to have “an important advisory role” in the evaluation of drugs and health technologies under a new value-based pricing initiative but will no longer be key to whether a particular drug receives government funding, according to a high-ranking National Health Service official.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor